Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium
October 17 2022 - 7:00AM
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the research and
discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that Lawrence Steinman,
Pasithea’s Chairman and National Academy of Sciences Professor,
will present preclinical proof of concept study results of the
Company’s tolerizing vaccine program in multiple sclerosis, PAS002,
on Oct. 14-17, 2022, at the Immunotherapy 2022 International Course
and Symposium in Buenos Aires, Argentina. PAS002 is a proprietary
DNA vaccine construct encoding GlialCAM.
During the Symposium, Prof. Lawrence Steinman
and Dr. James Allison, recipient of the 2018 Nobel Prize in
Medicine, will each be awarded an honorary doctorate by the
University of Buenos Aires. Other speakers will include Dr. Laurie
Glimcher, President and CEO of the Dana-Farber Cancer Institute in
Boston, and Prof. Ignacio Melero, Co-Director of the Department of
Immunology and Immunotherapy at the University of Navarra in
Spain.
“We look forward to presenting our data at an
international forum with other world-renowned leaders in MS and
immunotherapy,” said Dr. Tiago Reis Marques, CEO, Pasithea. “The
study results support the Company’s ongoing commitment to the
program and move us further along in our mission to uncover new and
effective treatments for neurological disorders.”
“It is an honor to be recognized alongside Dr.
Allison by the University of Buenos Aires, an institution that
promotes research and excellence,” added Prof. Steinman. “The field
of neurology, particularly for disabling diseases such as MS,
requires deep research into the nature of effective therapeutic and
immunization solutions. I have dedicated my career to propelling
these therapies forward for the thousands of people suffering from
neurological diseases around the world.”
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics is a biotechnology company
primarily focused on the discovery, research and development of
innovative treatments for central nervous system (CNS) disorders.
With an experienced team of experts in the fields of neuroscience
and psychopharmacology, Pasithea is developing new molecular
entities for the treatment of psychiatric and neurological
disorders, including Amyotrophic Lateral Sclerosis (ALS) and
Multiple Sclerosis, Neurofibromatosis type 1 and Noonan
syndrome.
ABOUT PAS002
PAS002 is an engineered DNA plasmid designed to
tolerize the immune system to GlialCAM.
About Multiple Sclerosis
Multiple Sclerosis (“MS”) is a chronic and
potentially disabling autoimmune disease, and the most common
neurodegenerative disease of the central nervous system in young
adults. The pathological hallmark of MS is the formation of
demyelinating lesions in the brain and spinal cord, with the immune
system attacking the myelin sheath that normally protects nerve
fibers in the brain, spinal cord, and optic nerve. There are now
2.8 million people worldwide who have MS, and every five minutes,
someone, somewhere in the world is diagnosed with this disorder.
While there is no way to predict with any certainty how an
individual’s disease will progress, four basic MS disease courses
(also called types or phenotypes) have been defined: clinically
isolated syndrome, relapsing remitting, secondary progressive and
primary progressive. The most common affecting around 85 per cent
of everyone diagnosed with MS is relapsing remitting MS (RRMS). It
means that symptoms appear (a relapse), and then fade away, either
partially or completely (remitting).
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Company ContactDr. Tiago Reis
MarquesChief Executive OfficerE: tiago@pasithea.com
Investor Relations ContactLisa
M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Media ContactsKCSA Strategic
CommunicationsRaquel Cona / Shana MarinoE: pasithea@kcsa.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jul 2023 to Jul 2024